Form 4: Gilead CFO Sells 3,000 Shares Under 10b5-1 Plan

Gilead Sciences CFO Andrew D. Dickinson sold 3,000 shares of common stock for $124.31 per share on January 15, 2026, under a pre-arranged 10b5-1 trading plan.

Summary

• Andrew D. Dickinson, Chief Financial Officer of Gilead Sciences, Inc. (GILD), reported a transaction involving the company's common stock.
• On January 15, 2026, Mr. Dickinson disposed of 3,000 shares of common stock.
• The shares were sold at a price of $124.31 per share.
• Following this transaction, Mr. Dickinson directly beneficially owns 150,503 shares of Gilead Sciences common stock.
• The transaction was executed pursuant to a Rule 10b5-1 trading plan, which was adopted on August 29, 2024.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While it's an insider sale, the execution under a pre-arranged 10b5-1 plan indicates a planned, non-opportunistic transaction, which is a positive for corporate governance and compliance. The relatively small number of shares sold also limits any negative interpretation.

Positives

• The transaction was conducted under a Rule 10b5-1 trading plan, indicating a pre-scheduled and compliant sale, which helps mitigate concerns about opportunistic insider trading.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived by the market as a lack of confidence, although the relatively small number of shares sold and the 10b5-1 plan mitigate this concern.

Risks

• No specific risks are mentioned in this Form 4 filing beyond the general market perception of insider selling.

Future Outlook

This Form 4 filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

Insider transactions, such as the sale of shares by a Chief Financial Officer, are common occurrences in publicly traded companies. Executives often use Rule 10b5-1 plans to diversify their personal holdings, manage tax liabilities, or for other personal financial planning purposes, without being accused of trading on material non-public information.

Corporate Governance

Stakeholder Impact

• Shareholders: May view the sale as a routine diversification or personal financial planning event, especially given the 10b5-1 plan. Without further context, it is unlikely to significantly impact shareholder confidence.

Key Dates

Recommendation

The sale of 3,000 shares by the CFO is a routine transaction executed under a pre-arranged 10b5-1 trading plan. This type of transaction is generally for personal financial planning or diversification and does not typically signal a change in the company's fundamental outlook or warrant a shift in investment recommendation for a large, established company like Gilead Sciences.

Keywords

Gilead Sciences, GILD, Form 4, Insider Trading, Stock Sale, CFO, 10b5-1 Plan, Executive Compensation